Search
Folic acid
go.drugbank.com/drugs/DB00158ApprovedInvestigationalNutraceuticalVet approvedMore specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. … [L5744] In order to function within the body, folic acid must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF).
Mixtures: Pnv-VP-U, Formula U - TabLeptin
go.drugbank.com/drugs/DB05098InvestigationalThus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite
Reboxetine
go.drugbank.com/drugs/DB00234ApprovedInvestigationalWithdrawnReboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.
Black cohosh
go.drugbank.com/drugs/DB13975Approved[A32543] The American College of Obstetrics and Gynecology guidelines on the use of botanicals, such as black cohosh, for the management of menopausal symptoms the use of for up to six months, especially
Acamprosate
go.drugbank.com/drugs/DB00659ApprovedInvestigationalIt was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.[L31783] … [A229073] Acamprosate, also known by the brand name Campral, is a drug used for the maintenance of alcohol abstinence.
Triethylenetetramine
go.drugbank.com/drugs/DB06824ApprovedInvestigational[A19333] Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,[A19334] TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and
CX-717
go.drugbank.com/drugs/DB05047IllicitInvestigationalCX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.
Ribociclib
go.drugbank.com/drugs/DB11730ApprovedInvestigationalRibociclib was approved by the FDA in March 2017 under the brand name Kisqali. … Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).
ZD4407
go.drugbank.com/drugs/DB06539ExperimentalIt entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.
Besilesomab
go.drugbank.com/drugs/DB13979ApprovedUtilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the